343 related articles for article (PubMed ID: 15964341)
1. The cost-effectiveness of basiliximab induction in "old-to-old" kidney transplant programs: Bayesian estimation, simulation, and uncertainty analysis.
Emparan C; Wolters H; Laukötte M; Senninger N
Transplant Proc; 2005 Jun; 37(5):2069-71. PubMed ID: 15964341
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of basixilimab induction and calcineurin-sparing protocols in "old to old" programs using Markov models.
Emparan C; Wolters H; Laukötter M; Dame C; Senninger N
Transplant Proc; 2003 Jun; 35(4):1324-5. PubMed ID: 12826149
[TBL] [Abstract][Full Text] [Related]
3. Long-term results of calcineurin-free protocols with basiliximab induction in "old-to-old" programs.
Emparan C; Wolters H; Laukötter M; Senninger N
Transplant Proc; 2004 Nov; 36(9):2646-8. PubMed ID: 15621113
[TBL] [Abstract][Full Text] [Related]
4. Bayesian estimation, simulation and uncertainty analysis: the cost-effectiveness of ganciclovir prophylaxis in liver transplantation.
Vanness DJ; Kim WR
Health Econ; 2002 Sep; 11(6):551-66. PubMed ID: 12203757
[TBL] [Abstract][Full Text] [Related]
5. Calcineurin-free protocols with basiliximab induction allow patients included in "old to old" programs achieve standard kidney transplant function.
Emparan C; Laukötter M; Wolters H; Dame C; Heidenreich S; Senninger N
Transplant Proc; 2003 Jun; 35(4):1326-7. PubMed ID: 12826150
[TBL] [Abstract][Full Text] [Related]
6. Polyclonal versus monoclonal induction therapy in a calcineurin inhibitor-free immunosuppressive therapy in renal transplantation: a comparison of efficacy and costs.
Sánchez-Escuredo A; Alsina A; Diekmann F; Revuelta I; Esforzado N; Ricart MJ; Cofan F; Fernandez E; Campistol JM; Oppenheimer F
Transplant Proc; 2015; 47(1):45-9. PubMed ID: 25645767
[TBL] [Abstract][Full Text] [Related]
7. Induction therapy with rabbit antithymocyte globulin versus basiliximab after kidney transplantation: a health economic analysis from a German perspective.
Cremaschi L; von Versen R; Benzing T; Wiesener M; Zink N; Milkovich G; Paivanas T; Gallagher M; Thaiss F
Transpl Int; 2017 Oct; 30(10):1011-1019. PubMed ID: 28556488
[TBL] [Abstract][Full Text] [Related]
8. Economic analysis of basiliximab in renal transplantation.
Keown PA; Balshaw R; Krueger H; Baladi JF
Transplantation; 2001 Jun; 71(11):1573-9. PubMed ID: 11435967
[TBL] [Abstract][Full Text] [Related]
9. Cost evaluation of basiliximab treatment for renal transplant patients in Japan.
Hasegawa T; Imai H; Miki S
Pharmacoeconomics; 2003; 21(11):791-806. PubMed ID: 12859220
[TBL] [Abstract][Full Text] [Related]
10. A prospective economic evaluation of basiliximab (Simulect) therapy following renal transplantation.
Lorber MI; Fastenau J; Wilson D; DiCesare J; Hall ML
Clin Transplant; 2000 Oct; 14(5):479-85. PubMed ID: 11048993
[TBL] [Abstract][Full Text] [Related]
11. Effect of basiliximab on renal allograft rejection within 1 year after transplantation.
Lee BM; Oh CK; Jin SH; Kim JH; Kim SJ; Kim H; Shin GT
Transplant Proc; 2006 Sep; 38(7):2025-8. PubMed ID: 16979988
[TBL] [Abstract][Full Text] [Related]
12. The economics of basiliximab (Simulect) in preventing acute rejection in renal transplantation.
Chilcott JB; Holmes MW; Walters S; Akehurst RL; Nashan B
Transpl Int; 2002 Oct; 15(9-10):486-93. PubMed ID: 12389081
[TBL] [Abstract][Full Text] [Related]
13. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
[TBL] [Abstract][Full Text] [Related]
14. Simulect induction facilitates Neoral-based steroid-free immunosuppression in primary kidney transplant recipients.
Kung SC; Parikh M; Fyfe B; Xiao SG; Sierka D; Heifets M; Moritz M; Anil Kumar MS
Transplant Proc; 2004 Mar; 36(2 Suppl):475S-477S. PubMed ID: 15041391
[TBL] [Abstract][Full Text] [Related]
15. Economic implications of the use of basiliximab in addition to triple immunosuppressive therapy in renal allograft recipients: a UK perspective.
Walters SJ; Whitfield M; Akehurst RL; Chilcott JB
Pharmacoeconomics; 2003; 21(2):129-38. PubMed ID: 12515574
[TBL] [Abstract][Full Text] [Related]
16. Limited-dose Daclizumab versus Basiliximab: a comparison of cost and efficacy in preventing acute rejection.
Pham K; Kraft K; Thielke J; Oberholzer J; Sankary H; Testa G; Benedetti E
Transplant Proc; 2005 Mar; 37(2):899-902. PubMed ID: 15848569
[TBL] [Abstract][Full Text] [Related]
17. Cost evaluation of basiliximab treatment for renal transplant patients in Japan.
Hasegawa T; Imai H; Miki S
Transplant Proc; 2003 Feb; 35(1):198-202. PubMed ID: 12591365
[No Abstract] [Full Text] [Related]
18. Comparative study of clinical outcome in kidney transplantation between early steroid withdrawal protocol using basiliximab, calcineurin inhibitor, and mycophenolate mofetil and triple regimen consisting of calcineurin inhibitor, mycophenolate mofetil, and steroid.
Teraoka S; Sato S; Sekijima M; Iwado K; Urashima Y; Kudo S; Kai K; Koyama I; Tojinbara T; Nakajima I; Fuchinoue S
Transplant Proc; 2005 Mar; 37(2):791-4. PubMed ID: 15848533
[TBL] [Abstract][Full Text] [Related]
19. Immunoprophylaxis with Simulect (basiliximab) in pediatric kidney transplant recipients: results from routine clinical practice at 5 kidney transplant units.
García Meseguer C; Vila López A; Luque de Pablos A; Vallo Boado A; Simon JM;
Transplant Proc; 2003 Aug; 35(5):1697-8. PubMed ID: 12962762
[TBL] [Abstract][Full Text] [Related]
20. PREventing Delayed Graft Function by Driving Immunosuppressive InduCtion Treatment (PREDICT-DGF): study protocol for a randomized controlled trial.
Chapal M; Foucher Y; Marguerite M; Neau K; Papuchon E; Daguin P; Morélon E; Mourad G; Cassuto E; Ladrière M; Legendre C; Giral M
Trials; 2015 Jun; 16():282. PubMed ID: 26099226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
